Chardan Capital analyst Daniil Gataulin initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $21.
What’s Going On With C3.ai Stock?
C3.ai, Inc. (NYSE: AI) shares are trading higher Tuesday, and the stock is up more than 14% over the past five days. Here's a look at what's going on:
What To Know: